Companies around the world are rushing to create a coronavirus vaccine in record time. But making enough doses and getting them to those who need it may prove to be the real challenge.
Government and private companies around the world have mobilized in an effort to develop a vaccine for the coronavirus at a record pace. The Trump administration earlier this month announced a program called Operation Warp Speed in hopes of having a viable vaccine ready by the end of the year.
Recent history has shown that even when an effective treatment for a dangerous disease exists, production and distribution issues can hamper the effort to help. In 2009, a limited number of an H1N1 swine flu vaccine led to “absolute desperation” for supplies, a state official said. The push to distribute a vaccine for Ebola in Africa was held back by confusion and lack of trust among the local population.
Vaccine distribution will be a massive undertaking for every government, but some of the president’s critics say the Trump administration is uniquely unequipped to handle it. Shortages of tests, certain drugs and protective equipment, which have plagued the U.S. response to the virus, may be signs of future scarcities when a vaccine is ready, they argue.
Who receives the vaccine may depend significantly on which country wins the race to create one. As many as 100 vaccines are currently in some stage of production. Projects in the U.S., China and the United Kingdom currently appear to be out in front. World leaders have expressed concern that whichever nation produces a vaccine first might hoard supplies for its own citizens at the expense of the rest of the world.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Here's why a coronavirus vaccine might be ready early next year—and what could go wrongScientists still don't fully understand key aspects of the deadly virus, including how immune systems respond once a person is exposed.
Weiterlesen »
Why a coronavirus vaccine might be ready early next year — and what could go wrongScientists still don't fully understand key aspects of the deadly virus, including how immune systems respond once a person is exposed.
Weiterlesen »
A Potential Coronavirus Vaccine Has Made It Through The First Testing Phase — With Promising ResultsNot only does the vaccine appear to be safe, it also seems to elicit the kind of immune response necessary to prevent disease.
Weiterlesen »
Thailand says it expects coronavirus vaccine next year after tests in miceThailand expects to have a vaccine for the novel coronavirus ready next year, a senior official said on Wednesday, after finding positive trial results in mice.
Weiterlesen »
U.S. to Invest $1.2 Billion to Secure Potential Coronavirus Vaccine From AstraZeneca, Oxford UniversityThe U.S. will bankroll a 30,000-person vaccine trial in the U.S. starting in the summer, plus the ramp-up of manufacturing capacity to make at least 300 million doses
Weiterlesen »